Trial Outcomes & Findings for Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes (NCT NCT02107976)
NCT ID: NCT02107976
Last Updated: 2026-05-12
Results Overview
Difference in mean AUC for RBC deformability half maximal shear stress (SS0.5) from baseline to the 8-week follow-up visit, using controlled hyperglycemia conditions (glucose 200-400 mg/dL). The insulin regimen will be withheld to produce controlled hyperglycemia \< 400 mg/dl. Subjects were provided a high carbohydrate diet (70-75% carbohydrate) on the day of hyperglycemia. During the hyperglycemic condition, blood samples will be drawn every one to two hours for RBC deformability measurements, between 7am and 10pm. AUC calculated from these serial measurements used the trapezoid rule and final measure are in units of Pa\*hr.
COMPLETED
NA
28 participants
Baseline to 8-week follow-up
2026-05-12
Participant Flow
Participant milestones
| Measure |
Diabetes
Male or female 18-65 years old with diabetes type 2, HgA1C = 12% on insulin and/or oral hypoglycemic agents, or any prior history or diagnosis of diabetes
|
Healthy
Male or female 18-65 years old without any prior history or diagnosis of diabetes.
|
|---|---|---|
|
Baseline
STARTED
|
16
|
12
|
|
Baseline
COMPLETED
|
14
|
12
|
|
Baseline
NOT COMPLETED
|
2
|
0
|
|
8-week follow-up
STARTED
|
14
|
12
|
|
8-week follow-up
COMPLETED
|
14
|
12
|
|
8-week follow-up
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
| Measure |
Diabetes
Male or female 18-65 years old with diabetes type 2, HgA1C = 12% on insulin and/or oral hypoglycemic agents, or any prior history or diagnosis of diabetes
|
Healthy
Male or female 18-65 years old without any prior history or diagnosis of diabetes.
|
|---|---|---|
|
Baseline
Lost to Follow-up
|
2
|
0
|
Baseline Characteristics
There were missing height or weight data such that BMI calculations are missing for 6 participants
Baseline characteristics by cohort
| Measure |
Diabetes
n=16 Participants
Type 2 diabetic subjects with HgA1C of \<=12% between the ages of 18 - 65 years old
|
Healthy
n=12 Participants
Non-diabetic controls between the ages of 18-65 years old.
|
Total
n=28 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
50.06 years
STANDARD_DEVIATION 11.89 • n=16 Participants
|
36.33 years
STANDARD_DEVIATION 16.25 • n=12 Participants
|
44.18 years
STANDARD_DEVIATION 15.30 • n=28 Participants
|
|
Sex: Female, Male
Female
|
10 Participants
n=16 Participants
|
3 Participants
n=12 Participants
|
13 Participants
n=28 Participants
|
|
Sex: Female, Male
Male
|
6 Participants
n=16 Participants
|
9 Participants
n=12 Participants
|
15 Participants
n=28 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=16 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=28 Participants
|
|
Race (NIH/OMB)
Asian
|
3 Participants
n=16 Participants
|
1 Participants
n=12 Participants
|
4 Participants
n=28 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=16 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=28 Participants
|
|
Race (NIH/OMB)
Black or African American
|
5 Participants
n=16 Participants
|
5 Participants
n=12 Participants
|
10 Participants
n=28 Participants
|
|
Race (NIH/OMB)
White
|
7 Participants
n=16 Participants
|
5 Participants
n=12 Participants
|
12 Participants
n=28 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=16 Participants
|
1 Participants
n=12 Participants
|
1 Participants
n=28 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=16 Participants
|
0 Participants
n=12 Participants
|
1 Participants
n=28 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
2 Participants
n=16 Participants
|
1 Participants
n=12 Participants
|
3 Participants
n=28 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
13 Participants
n=16 Participants
|
11 Participants
n=12 Participants
|
24 Participants
n=28 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=16 Participants
|
0 Participants
n=12 Participants
|
1 Participants
n=28 Participants
|
|
BMI
|
32.6 kg/m2
STANDARD_DEVIATION 5.5 • n=11 Participants • There were missing height or weight data such that BMI calculations are missing for 6 participants
|
24.9 kg/m2
STANDARD_DEVIATION 4.0 • n=11 Participants • There were missing height or weight data such that BMI calculations are missing for 6 participants
|
28.7 kg/m2
STANDARD_DEVIATION 6.1 • n=22 Participants • There were missing height or weight data such that BMI calculations are missing for 6 participants
|
PRIMARY outcome
Timeframe: Baseline to 8-week follow-upPopulation: The analysis population is composed of those that completed RBC deformability serial lab values for both the baseline and 8-week follow-up. One participant with diabetes had missing values and this outcome was not able to be calculated for that participant.
Difference in mean AUC for RBC deformability half maximal shear stress (SS0.5) from baseline to the 8-week follow-up visit, using controlled hyperglycemia conditions (glucose 200-400 mg/dL). The insulin regimen will be withheld to produce controlled hyperglycemia \< 400 mg/dl. Subjects were provided a high carbohydrate diet (70-75% carbohydrate) on the day of hyperglycemia. During the hyperglycemic condition, blood samples will be drawn every one to two hours for RBC deformability measurements, between 7am and 10pm. AUC calculated from these serial measurements used the trapezoid rule and final measure are in units of Pa\*hr.
Outcome measures
| Measure |
Diabetes
n=13 Participants
Type 2 diabetic subjects with HgA1C of \<=12% between the ages of 18 - 65 years old
|
Healthy
n=12 Participants
Non-diabetic controls between the ages of 18-65 years old.
|
|---|---|---|
|
Diff AUC SS0.5 Hyperglycemic
|
0.74 Pa*hr
Standard Deviation 4.09
|
0.96 Pa*hr
Standard Deviation 2.52
|
SECONDARY outcome
Timeframe: Baseline to 8-week follow-upPopulation: Not all required values for calculation were available for one healthy participant and one participant with diabetes
The elongation index (EI) measures the degree of red blood cell deformity (elongation). EI is calculated by (L-W)/(L+W), where L and W are the length and width of the diffraction pattern. EI values are automatically reported by the ektacytometry software, with lower values indicating worse RBC deformability at the corresponding shear stress. Difference in mean AUC for RBC deformability elongation indices (EI) from baseline to 8-week follow-up as assessed through serial serum samples taken every hour or two from 7am to 10pm. EI are unitless and are reported using arbitrary units (AU). AUC calculated from these serial measurements used the trapezoid rule and the final measure is in units of AU\*hr.
Outcome measures
| Measure |
Diabetes
n=13 Participants
Type 2 diabetic subjects with HgA1C of \<=12% between the ages of 18 - 65 years old
|
Healthy
n=11 Participants
Non-diabetic controls between the ages of 18-65 years old.
|
|---|---|---|
|
Diff AUC RBC EI
|
0.05 AU*hr
Standard Deviation 0.31
|
-0.07 AU*hr
Standard Deviation 0.21
|
SECONDARY outcome
Timeframe: Baseline to 8-week follow-upPopulation: The analysis population is composed of those that completed RBC deformability serial lab values for both baseline and 8-week follow-up. One participant with diabetes had missing values and this outcome was not able to be calculated for that participant.
Difference in mean AUC for RBC deformability maximum elongation indices (EImax) from baseline to 8-week follow-up, while using controlled hyperglycemia conditions (glucose 200-400 mg/dL). The insulin regimen will be withheld to produce controlled hyperglycemia \< 400 mg/dl for a maximum of 9 hours. Subjects were provided a high carbohydrate diet (70-75% carbohydrate) on the day of hyperglycemia. During the 9 hour duration of the hyperglycemic condition, blood samples will be drawn every one to two hours for RBC deformability EImax. AUC calculated from these serial measurements used the trapezoid rule and final measures are in units of Pa\*hr.
Outcome measures
| Measure |
Diabetes
n=13 Participants
Type 2 diabetic subjects with HgA1C of \<=12% between the ages of 18 - 65 years old
|
Healthy
n=12 Participants
Non-diabetic controls between the ages of 18-65 years old.
|
|---|---|---|
|
Diff AUC RBC EImax, Hyperglycemic
|
-0.08 Pa*hr
Standard Deviation 0.27
|
-0.02 Pa*hr
Standard Deviation 0.10
|
SECONDARY outcome
Timeframe: Baseline to 8-week follow-upPopulation: The analysis population is composed of those that completed RBC deformability serial lab values for both the baseline and 8-week follow-up. One participant with diabetes had missing values and this outcome was not able to be calculated for that participant.
Difference in mean AUC for RBC deformability maximum elongation indices (EImax) from baseline to 8-week follow-up, while maintaining euglycemic condition (premeal and fasting glucose \<140 mg/dl). When euglycemic conditions are achieved, an intravenous catheter will be inserted and euglycemic blood samples will be drawn every one to two hours, between 7am and 10pm, for RBC deformability EImax. AUC will be calculated from these serial measurements using the trapezoid method in units of Pa\*hr
Outcome measures
| Measure |
Diabetes
n=13 Participants
Type 2 diabetic subjects with HgA1C of \<=12% between the ages of 18 - 65 years old
|
Healthy
n=12 Participants
Non-diabetic controls between the ages of 18-65 years old.
|
|---|---|---|
|
Diff AUC RBC EImax Euglycemic
|
-0.06 Pa*hr
Standard Deviation 0.19
|
-0.01 Pa*hr
Standard Deviation 0.10
|
SECONDARY outcome
Timeframe: Baseline to 8-week follow-upPopulation: The analysis population is composed of those that completed RBC deformability serial lab values for both baseline and 8-week follow-up. One participant with diabetes had missing values and this outcome was not able to be calculated for that participant.
For the first 24-48 hours, for participants with diabetes, insulin doses will be titrated to achieve and maintain euglycemia (premeal and fasting glucose \<140 mg/dl). When euglycemic conditions are achieved, an intravenous catheter will be inserted and euglycemic sampling initiated; blood samples will be drawn every one to two hours for RBC deformability measurements, from 7am to 10pm. AUC will be calculated from these serial measurements using the trapezoid method in units of Pa\*hr; the difference in mean AUC for RBC deformability half maximal shear stress (SS0.5) from baseline to the 8-week follow-up visit is reported.
Outcome measures
| Measure |
Diabetes
n=13 Participants
Type 2 diabetic subjects with HgA1C of \<=12% between the ages of 18 - 65 years old
|
Healthy
n=12 Participants
Non-diabetic controls between the ages of 18-65 years old.
|
|---|---|---|
|
Diff AUC SS0.5 Euglycemic
|
1.1 Pa*hr
Standard Deviation 5.29
|
0.37 Pa*hr
Standard Deviation 2.91
|
Adverse Events
Diabetes
Healthy
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place